Browse News

Found 155 articles

• Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection

  9/21/2023

  Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA ® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection.

• DZD Awarded SBIR Grant for Development of Microbiome Diagnostics

  8/29/2023

  Day Zero Diagnostics Inc., a pioneer in infectious disease diagnostics, has received a Phase I Small Business Innovation Research award from the National Institute of Allergies and Infectious Disease of the National Institutes of Health.

• Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

  8/8/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business updates.

• Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology

  7/11/2023

  Ferring Pharmaceuticals today announced that Therapeutic Advances in Gastroenterology has published an integrated safety analysis from five prospective clinical trials for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent C. diff infection after antibiotic treatment.

• Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

  6/22/2023

  Ferring Pharmaceuticals announced that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.

• Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

  6/17/2023

  Seres Therapeutics, Inc. and Nestlé Health Science announced the presentation of a post-hoc analysis from the Phase 3 development program for VOWST™, the first and only U.S. Food and Drug Administration -approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI.

• Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen

  6/15/2023

  Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen.

• Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

  6/5/2023

  Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection.

• Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

  5/30/2023

  Seres Therapeutics, Inc. announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI.

• Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201

  5/17/2023

  Lumen Bioscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for LMN-201, an investigational, orally delivered biologic drug to treat and prevent C. difficile infection (CDI).

• Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/9/2023

  Seres Therapeutics, Inc., a leading microbiome therapeutics company, reported first quarter 2023 financial results and provided business updates.

• PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

  5/9/2023

  PureTech Health plc announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

• Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

  5/8/2023

  Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

• Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

  5/8/2023

  Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

• Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™

  5/8/2023

  Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting.

• 

  Seres’ Vowst Wins FDA First-Ever Approval for Oral Microbiome Therapeutic

  4/27/2023

  Vowst, the first-ever oral fecal microbiome-based therapeutic, is indicated for preventing C. diff recurrence in adults following antibacterial treatment.

• Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

  4/27/2023

  Seres Therapeutics, Inc. and Nestlé Health Science announced the U.S. Food and Drug Administration approval of VOWSTTM, formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI.

• FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

  4/26/2023

   Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally.

• 

  Vedanta Raises $106.5M to Advance New Class of C. diff Therapeutics

  4/25/2023

  Vedanta will use the funds to advance its lead asset VE303 in clostridioides difficile infection and support the development of another candidate in ulcerative colitis.

• Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023

  4/18/2023

  Ferring to Present Analyses of Data for REBYOTA ™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023.